Stock Events

Stock Events

Indaptus Therapeutics 

$1.78
0
+$0+0% Wednesday 01:04

Statistics

Day High
1.78
Day Low
1.78
52W High
-
52W Low
-
Volume
2
Avg. Volume
-
Mkt Cap
3.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-4.36
-3.53
-2.7
-1.87
Expected EPS
-1.87
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-30.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INDP.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, which is a platform that can potentially compete with Indaptus Therapeutics' approach to immunotherapy and vaccine development.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech, similar to Moderna, specializes in mRNA technology for vaccines, directly competing in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.36B
Novavax is involved in the development of vaccines for infectious diseases, which could compete with Indaptus Therapeutics' vaccine programs.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that focuses on antiviral drugs and other treatments that could compete with Indaptus Therapeutics' therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in creating monoclonal antibodies, which could be in direct competition with any antibody-based therapies developed by Indaptus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments in immunology, which could overlap with Indaptus Therapeutics' focus areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a broad portfolio, including vaccines and immunotherapies that could compete with Indaptus Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines that could compete with Indaptus' offerings.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in the development of vaccines and treatments for infections and diseases, potentially competing with Indaptus Therapeutics.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is known for its vaccines and anti-infective treatments, which could directly compete with Indaptus Therapeutics' development programs.

About

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Show more...
CEO
ISIN
US45339J2042

Listings

BOATS
BOATS
INDP.BOATS
XNAS
US
INDP

0 Comments

Share your thoughts

FAQ

What is Indaptus Therapeutics stock price today?▼
The current price of INDP.BOATS is $1.78 USD — it has increased by +0% in the past 24 hours. Watch Indaptus Therapeutics stock price performance more closely on the chart.
What is Indaptus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Indaptus Therapeutics stocks are traded under the ticker INDP.BOATS.
What is Indaptus Therapeutics market cap?▼
Today Indaptus Therapeutics has the market capitalization of 3.12M
When is the next Indaptus Therapeutics earnings date?▼
Indaptus Therapeutics is going to release the next earnings report on May 07, 2026.
What is Indaptus Therapeutics revenue for the last year?▼
Indaptus Therapeutics revenue for the last year amounts to 0 USD.
What is Indaptus Therapeutics net income for the last year?▼
INDP.BOATS net income for the last year is -30.04M USD.
When did Indaptus Therapeutics complete a stock split?▼
Indaptus Therapeutics has not had any recent stock splits.